Trial Profile
A pivotal study evaluating Amitza (lubiprostone) in patients with chronic idiopathic constipation
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2018
Price :
$35
*
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Registrational; Therapeutic Use
- Sponsors Harbin Gloria Pharmaceuticals
- 13 Feb 2018 According to a Mallinckrodt plc media release, Sucampo Pharmaceuticals is acquired by Mallinckrodt.
- 16 Jun 2015 New trial record
- 15 Jun 2015 The China FDA accepted an IND application for a pivotal study of Amitza in patients with chronic idiopathic constipation, according to a Sucampo Pharmaceuticals media release.